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Target cell lysis can be achieved by different specific effector mechanisms:  antibody 
and complement  (complement-dependent  lysis, [CDL]I), antibody and K  cells (anti- 
body-dependent  cell-mediated  cytotoxicity,  [ADCC])  or  cytolytic  T  lymphocytes 
(CTL). Little is known about how the target antigens have to be presented on the cell 
membrane  to  allow  specific  target  cell  lysis  and  whether  the  different  effector 
mechanisms have similar structural  requirements  for cytolysis. We have studied these 
questions in a  model system in which purified viral spike proteins were used as target 
cell  antigens.  We were  particularly  interested  in  finding  out  whether  it  is sufficient 
that viral antigens are bound to cells or whether integration  of the viral antigens into 
the  lipid  bilayer of the  plasma membrane  is a  prerequisite  for cytolysis.  Our earlier 
data  (1,  2)  indicated  that  viral  antigen  integration  is  required  for  lysis  by  H-2- 
restricted CTL. In this report we studied this question with respect to cytolytic events 
involving antibodies. 
We have used Semliki Forest virus (SFV), a membrane virus which is assembled by 
a  budding  process.  SFV  has only one spike  protein,  composed of three  polypeptide 
chains,  which  is inserted  into  the plasma  membrane at  the  budding  site.  This spike 
protein can be prepared from purified SFV in three different  physical forms:  (a) as a 
monomer bound to detergent  (3), (b) as a  practically lipid- and detergent-free protein 
micelle in an octamerous  form  (29S complex)  (4), or (c) reconstituted  into detergent- 
free lipid vesicles--so-called virosomes (5). 
The  micelles  and  most  likely  also  the  virosomes  attach  to  receptors  on  the  cell 
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surface, which are shown to be the histocompatibility antigens  (6).  The requirements 
of viral antigen expression on tumor target cells for immune cytolysis were studied by 
comparing target  cells for immune cytolysis were studied  by comparing target  cells 
prepared  in  three  different  ways:  (a)  virus-infected  cells,  where  the  antigens  are 
integrated  into  the  cell  membrane  from within,  (b)  cells  bearing  the  viral  antigens 
attached  to receptors on the cell surface, and  (c)  cells which have the viral  antigens 
integrated  into  the  cell  membrane  from  the  outside  by fusion  of target  cells  with 
virosomes. Because the virosomes did not fuse spontaneously with the cell membrane, 
we used Sendai virus to facilitate the fusion (Fig.  1). 
Immune cytolysis of target cells was measured  by the 5aCr-release  technique  after 
incubation  with  either  anti-viral  antibodies  and  complement  (CDL)  or  anti-virus 
antibody and  K  cells  (ADCC).  In addition,  in selected  experiments  anti-virus  CTL 
were also employed. We will show that viral antigen binding to cells is not sufficient 
and  that  integration  of viral  glycoproteins  is  a  prerequisite  for anti-viral  immune 
cytolysis in all three assays investigated. 
Materials  and Methods 
Virus and Preparation of Virus Antigen.  A prototype strain of  SFV was propagated in monolayer 
cell cultures of BHK-21 cells. The culture procedure, virus purification, and  purity controls 
were performed as described by K/i~iri~iinen et al. (7). The lipid-free octamer membrane protein 
complexes  (protein  micelles),  which  have  an  s  of 29S  (therefore  also  referred  to  as  29S 
complexes),  were prepared  by solubilization  of whole virus  with  Triton  X-100 followed by 
centrifugation  through  a  top-layer  zone  of Triton  X-100  into  a  20-50%  sucrose  gradient 
according to Helenius and Bonsdorff (4). Liposomes with inserted  virus spike proteins  (viro- 
somes) were prepared with the octylglycoside dialysis method of Helenius et al. (5). The protein 
content  of the  virus  preparations  was determined  by the  Lowry method  (8)  with  3.5  mM 
sodium dodecyl sulfate in the reaction mixture. 
Sendai virus (SV) was grown in the allantoic cavity of 10-d-old embryonated chicken eggs. 
The virus was concentrated from the allantoic fluid by centrifugation at  120,000 g for 1 h at 
4°C. It was resuspended in phosphate-buffered saline (PBS)  and purified by density-gradient 
centrifugation (20-50% sucrose (wt/vol)) in PBS at  100,000 g for 2 h at 4°C. Purified SV was 
inactivated with/~-propiolactone (BPL) (9). Proteolytic digestion of BPL-treated SV (BPL-SV) 
was achieved either by trypsin, which cleaves the fusion protein  (F)  (10), or by V8 protease 
from Staphylococcus aureus which removes the hemagglutinin-neuraminidase  (HN) glycoprotein 
(2). 
Antisera.  Mouse  anti-SFV  serum  was prepared  by inoculating  104  plaque-forming units 
(pfu) of SFV A774 strain (11) i.p.  into BALB/c mice. The mice were bled  17 d after infection 
(BALB/c a-SFV). Rabbit anti-SFV serum (Rab a-SFV) was prepared by immunizing rabbits 
with  purified spike proteins of SFV in the oetamer complex (protein micelles)  form. It was 
kindly  provided  by  Dr.  K.. Simons,  European  Molecular  Biology Laboratory,  Heidelberg, 
Federal  Republic  of Germany.  Mouse  anti-SV  serum  was raised  in  DBA/2  mice by three 
injections of 100 hemagglutinating units i.p. at weekly intervals. The mice were bled 15 d after 
the last injection (DBA/2 a-SV). Rabbit anti-SV(F) serum was an antiserum against purified 
SV F. It was kindly  a provided by Dr. M.-J. Gething, Imperial Cancer Research Fund, London, 
England. Anti H-2  serum was prepared by 6-10 repeated immunizations of CBA/J mice with 
107  spleen  cells  from  a  BALB/c  mouse  (CBA/J  a-BALB/c)  i.p.  Anti-non-H-2  serum  was 
obtained by grafting DBA/2 skin onto B10.D2 mice followed 22 and 32 d later by a challenge 
with  10  v DBA/2 spleen cells i.p.  (B10.D2 a-DBA/2). It was a gift from Dr. Berenice Kindred, 
Heidelberg, Federal Republic of Germany. 
Complement.  Normal rabbit serum, absorbed with mouse spleen cells, served as a source of 
complement when using P815 cells as target cells. Normal guinea pig serum (Behring Werke 
AG, Marburg/Lahn, Federal Republic of Germany), absorbed with agarose and sheep eryth- 
rocytes, was used in CDL assays using Eb cells as target cells. B.  MOREIN,  D.  BARZ, U.  KOSZINOWSKI, AND V.  SCHIRRMACHER  1385 
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F1o.  1.  Schematic  drawing of the preparation of SFV antigens in different  physical forms and of 
their use in target cell generation showing three different characteristics  of antigen presentation: (a) 
cells expressing the viral antigens bound to receptors on the cell surface by attachment of SFV-29S 
complexes or by incubation with SFV-virosomes, (b) cells expressing the viral antigens integrated in 
the  cell  membrane from  within by  SFV  infection, and  (e)  cells  expressing  the  viral antigens 
integrated in the cell membrane from without by incubation  with virosomes from SFV under fusion 
conditions. TX 100, Triton X-100. 
Effector Cells 
K  (]ELLS.  Human peripheral blood lymphocytes obtained by the  Isopaque-Ficoll (Phar- 
maeia Fine Chemicals Inc., Div. of Pharmacia, Inc., Piscataway, N. J.) separation method (12), 
were used as effeetor cells in ADCC assays. 
CTL.  Anti-SV-speeific CTL were generated as described (13).  They were secondary CTL 
from DBA/2 mice sensitized in vivo and restimulated in vitro. 
Target Cells.  The tumor cell lines P815 (a mastocytoma cell) and Eb (a lymphoma cell) (14) 
are both derived from DBA/2 (H-2  d) mice. They were grown in suspension culture at 37°C in 
a  5% CO2 atmosphere using RPMI-1640 medium supplemented with  10% fetal calf serum, 2 
mM  L-glutamine, 50  U/ml  penicillin 50 #g/ml  streptomycin, and  10  mM  Hepes,  pH  7.3 
(complete RPMI-1640 medium). The cells were  harvested in the exponential growth  phase. 
fil  6  They were incubated with viral antigens and labeled with 25 gCi  Cr per 10  cells at the same 
time (see  below for incubation times).  Before  using the cells in a  cytotoxic assay, they were 
washed and the viability was determined by trypan blue exclusion. Target cells carrying the 
virus spikes integrated  into the  cell membrane from  within were  prepared  for one cycle of 
infection by incubation with 10-100 pfu of SFV per cell in serum-free medium for 1 h at 37°C 
in a  total vol of 200 ~1. Thereafter,  1 ml of complete RPMI-1640 medium was added per  l0  s 
cells and they were further incubated for 3 h. 29S complexes from SFV were bound to the cell 
6  surface by incubation of 5-10 #g of the mieelles per 10  cells in RPMI-1640 medium buffered 
to pH  7.0 or to pH  6.5 with  2-(N-morpholino)ethane sulfonic acid  (MES).  Virosomes were 
bound to the cell surface by incubation of 2-5 p.g virus protein with the cells under similar 
conditions as  for  the  29S  complexes.  Integration  of SFV  membrane protein  into  the  cell 
membrane from outside was achieved by incubation of cells with 5 #g virosomes per 106 cells 
and with SV with active fusion activity (amounts specified in legends to figures) for  1-4 h  at 
37°C in complete RPMI-1640 medium. 29S complexes (10 #g/10  cells) were also incubated 1386  SPECIFIC CYTOLYSIS AFTER  VIROSOME-TARGET  CELL FUSION 
with SV as described for virosomes. Further controls included incubation  of cells with virosomes 
and SV with inactivated HN or F. 
Assays 
INDXRECT IMMtrr~OFLUORESCENCE (nv).  IIF was performed as described by M611er (15). 106 
cells in 40/xl medium and 10 p.l 1:10-diluted Rab c~-SFV serum were incubated for 30 min on 
ice.  The cells  were  washed  twice and suspended in 50  /~1  medium plus 50 /xl  l:50-diluted 
fluorescein isothiocyanate (FITC)-conjugated pig anti-rabbit Ig serum (Nordic Immunological 
Laboratories, Tilburg, The Netherlands) and incubated further on ice for 30 min. The cells 
were  washed  twice in PBS,  pH  7.4, and fixed  in 50 #1 of  1.8% paraformaldehyde at  room 
temperature for 10 min. Thereafter, the cells were washed again in PBS and mounted on glass 
slides. In the case where the cells were coated with virosomes or micelles, the medium used was 
buffered to pH 6.5 with MES except  for the mounting buffer, which had a  pH of 7.4. The 
above antisera were always preabsorbed with the same cells on which they were used. 
ANT1~ODY A~soar,  rxoN.  1 ml of antiserum was preincubated with 1.2 ×  107 of the different 
target cells for 30 rain on ice and the remaining cytolytic activity of the antiserum was tested 
by CDL of SFV-infected target cells. 
COMPLEMENT CONSUM~rxoN.  The hemolytic complement activity left  in the supernate of 
CDL was determined as described (16). 
IMMUNE c~CrOLYSlS ASSAYS.  The cytolysis of target cells was assayed in a 5XCr-release test (17, 
18), performed  in round-bottom microtiter plates  (Linbro Chemical Co.,  Hamden, Conn., 
model IS-MRC 96). In CDL 2 ×  104 target cells in a vol of 25 ~1 were incubated with 25/~1 
diluted antiserum and 25 p.l complement for  1 h  at 37°C. After incubation, 125 ~tl of cold 
medium was added. In ADCC 2 X  104 target cells in a vol of 75/~1 were incubated with 25 ~1 
diluted antiserum and 1 ×  106 effector  cells in 100/~1 for 4 h at 37°C. In T-cell lysis (CTL)  1 
x  104 target cells in 100/~1 of medium were incubated together with four different concentra- 
tions of effector  cells for 4 h at 37°C. In all cytolysis assays the plates were centrifuged at the 
end of the incubation  period for 10 min at 375 g. 100 ~1 samples of the supernates were removed 
and the radioactivity determined in a gamma counter (Wallac Ultrogramma; LKB Produkter, 
Bromma,  Sweden).  Results  are  given as  the  percentage of specific  SXCr release  and  were 
calculated from triplicates according to the formula: 
experimental counts per minute -  low control 
percentage of specific 51Cr release  --  high control -  low control  ×  100. 
High controls were obtained by incubation of the target cells with detergent. The release from 
cells  incubated without antiserum but in the  presence of complement is referred to as low 
control in CDL. In the ADCC and T-cell lysis systems,  the spontaneous release  of target cells 
incubated without effector cells was taken as low control. 
Results 
Binding and Redistribution of SFV Spike Glycoprotein on Murine Tumor Cell Lines.  Before 
starting the cytolysis assays, the optimal conditions for binding of the viral antigens 
to the murine target cells (P815 and Eb) were determined by IIF. With 29S complexes, 
maximum intensity of fluorescence was obtained with  10/.tg of spike protein per  106 
cells, after incubation on ice for 30 rain at pH 6.5.  2 Fluorescence was detectable using 
as little as 0.5/~g of spike protein. With virosomes a maximum intensity of fluorescence 
was  obtained with  2-5  /~g  of spike  protein/106 cells.  More  than  95%  of the  cells 
incubated with the 29S complexes or the virosomes showed fluorescence which under 
noncapping conditions had a  patchy distribution (Fig. 2 A  and B). After infection of 
Eb or P815 cells with SFV, >95% of the cells were again positive in IIF (Fig. 2 C). No 
fluorescence was observed with control cells without viral antigens. 
Redistribution of viral antigens on the tumor cell membranes was investigated after 
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incubation of the antibody-coated cells at 37°C. More than 90% of the cells showed 
cap formation after incubation with 29S Complexes and rabbit anti-viral antibodies, 
followed by incubation for 2 h at 37°C with the FITC-eonjugated pig or sheep anti- 
rabbit  Ig  (Fig.  2D).  When  the  capped  cells  were  again  incubated  with  the  29S 
complexes and assayed in IIF with rhodamine-conjugated sheep anti-rabbit serum no 
fluorescence was observed on the stripped areas of the cell. 
Target  Cells  with  Viral Antigens  Attached to  the  Cell Membrane are  Resistant  to Immune 
Cytolysis.  P815  cells  carrying  viral  antigens  as  integral  membrane  proteins  after 
infection with SFV, were lysed by anti-SFV antiserum and complement (Fig. 3). 3 No 
target cell lysis, however, was seen when the tumor cells carrying SFV 29S complexes 
(Fig.  2A)  were  incubated  with  anti-SVF  serum  and  complement  under  the  same 
conditions (Fig. 3). In spite of their resistance to lysis, the target cells bound antibody 
and consumed even more complement than the virus-infected cells (Table I). 
To exclude the  possibility that  the cells after attachment  of viral antigens  were 
generally resistant  to  lysis,  several antisera  against  other cell surface determinants 
were tested. As illustrated in Fig. 3, an antiserum against non-H-2 membrane antigens 
(B10.D2 a-DBA/2)  lysed untreated, virus-infected and  29S-coated target cells with 
equal  efficiency. When  using an  antiserum  against  H-2 antigens,  29S-coated cells 
were generally lysed less efficiently than untreated or virus-infected cells. This blocking 
effect of H-2-specific lysis by 29S complexes was found with reproducibility in  l0 out 
of 12 experiments and ranged between 20 and 70% inhibition. 
Analogous experiments were performed with  a  different immune cytolysis tech- 
nique, ADCC, in which K  cells are added to the system instead of complement. The 
results obtained in ADCC were very similar to those obtained in C:DL (Fig. 4). Thus, 
the inability of anti-virus antibody to lyse target cells carrying SFV-29S complexes on 
the surface, does not seem to be restricted to the complement system. 
Target Cells with  Viral Antigens Integrated into the Cell Membrane  via Fusion are Susceptible 
to Immune Cytolysis.  The difference in susceptibility to lysis of virus-infected cells and 
29S  complex-coated cells suggested  that  integration  of viral  antigens  into  the  cell 
membrane may be required for immune cytolysis. To test this hypothesis directly, we 
tried to integrate the purified viral antigens from outside into the cell membrane via 
fusion of SFV virosomes as outlined in Fig.  1. The target cells incubated with SFV 
virosomes were resistant to lysis by anti-SFV antibody and complement (Figs.  3 and 
5). The cells, however, became susceptible for SFV-specific lysis when together with 
SFV  virosomes  BPL-treated  SV  was  added  as  a  fusing  reagent  (Fig.  5C).  Ceils 
incubated with SFV-29S complexes remained resistant to lysis even in the presence of 
SV. 
The same target cell preparations were also tested in the ADCC assay. The results 
(Fig.  6)  were in  every aspect  analogous  to those reported above for the CDL  test. 
Thus the K cells in the presence of antibody to SFV lysed target cells incubated with 
virosomes and SV with fusion activity, but not cells incubated with  29S complexes 
and the same preparation of SV. 
Further evidence for fusion of the virosomes with the cell membrane as the decisive 
factor which made the cells susceptible to immune lysis was obtained from control 
a This lysis appears to follow the alternative pathway of complement activation ([20] and Barz et al. 
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FIG. 2A, B 
Fro.  2.  IIF of target cells. (A) P815 cells incubated with SFV-29S complexes. × 4,000. (B) P815 
cells incubated with SFV-virosomes. X 1,500. (C) P815 cells infected with SFV. × 4,000. (D) P815 
cells incubated with SFV-29S complexes under capping conditions. ×  15,000. 
experiments with SV preprations lacking the fusion capacity:  (a)  trypsin-treated SV 
(Tryp-SV), which has similar binding capacity as BPL-SV but carries an inactive F 
and (b) staphylococcus protease-treated SV (Staph-SV), which lacks the HN protein 
and therefore cannot bind and mediate fusion. These and the untreated SV prepa- B. MOREIN, D.  BARZ, U.  KOSZINOWSKI, AND V.  SCHIRRMACHER  1389 
Fig.  2 C, D 
rations were tested not only for their capacity to mediate SFV-specific lysis but also 
to function as targets for SV-specific lysis (CDL, ADCC). In addition, SV-specific T- 
cell mediated lysis was tested which was previously found to be a very sensitive assay 
for the detection of membrane-integrated SV. The results (Figs. 5 and 6) showed: (a) 
SFV-specific lysis via virosomes (CDL, ADCC) was not facilitated by SV preparations 
without fusion capacity;  (b) in tests for SV-specific lysis (CDL, ADCC), only the SV 
preparation with fusion capacity was able to generate appropriate target cells. 1390  SPECIFIC  CYTOLYSIS  AFTER  VIROSOME-TARGET  CELL  FUSION 
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Fla.  3.  CDL of P815 cells expressing SFV spike protein by virus infection or by attachment of the 
purified spike proteins as 29S complexes or virosomes. (O) Nontreated P815 cells; (ll) SFV-infected 
P815. cells; (&) P8t5 cells with SFV-29S complexes bound to the cell surface; (0) P815 cells with 
SFV-virosomes bound to the cell surface. 
TABLE  I 
Binding of Antibody and of Complement to Cells Infected with SFV or Coated with SFV-29S Complexes 
Conditions in CI)L  Noatreated cell,,  SFV-infccled ~e|ls 
Antiserum  C' 
Ct~lls +  SFV-29S complexes 
Remain-  Remain-  Remain-  Renlain-  Remain-  Remain- 
~lCr re-  ing corn-  ing anti-  ~lCr' re-  in  n  corn  ing anti  ;ICr re-  ing corn-  ing anti- 
lease*  plement  body a~.-  lease*  plcment  body ac-  lease*  plement  body ac- 
actlvity:~  tivity§  activity~  tivlty§  activity:~  tiviu, § 
,;,  ,/,  ,,, 
--  --  4  7  --  6  7  --  9  9  -- 
+  5  41  --  7  32  --  t 0  30  --- 
Rabbit a-.'SFV  +  4  43  71  52  15  26  9  9  9 
1:25 
CBA  a-BALB/c  +  78  24  9  82  22  7  76  27  9 
1:25 
The  capacity  of the different target cells to bind specific  antibodies and complement (C') was compared with their ability to mediate C|)I,. 
* The percentage of nSCr release  of the different  Eb target cells  in a CI)L test. 
:~ The percentage of remaining hemolytic activity of the complement in supernates of CD1.  test performed  analogous to those in the 51Cr-r'elease assay 
but with unlabeled target cells:  for each  group 3-5 samples of supernate were pooled and tested against sensitized eiythrocytcs as described  [16) 
§ The percentage of remaining cytolytic activity of the antiserum when preabsorbed  on either nontreated, SFV-infccted, or 29S conlplex-coated cells 
(P815} and then tested in a Cl/I, test on SFV-infected P815 target cells; fol conditions of the absorption, see Material and Methods. 
All  the  differently  treated  target  cells  could  be  lysed  by  H-2  alloantibodies  and 
complement. 
When testing the same target cell preparations for susceptibility to immune cytolysis 
by  specific  CTL,  similar results were obtained  again  (Fig.  7).  SV-specific  CTL  were 
shown  to  lyse  only  those  tumor  target  cells  which  were  sensitized  with  BPL-SV 
carrying active HN  and F. When either of these proteins was destroyed or inactivated 
by  enzymatic  pretreatment,  no  sensitization  of  target  cells  for  lysis  was  observed. 
Incubation  of ceils with 0.1  #g of SV  was found  sufficient  for target  cell formation  in 
the  CTL  assay,  but  incubation  with  even  50  ~g  of Tryp-SV  or  Staph-SV  did  not 
make the cells susceptible  to SV-specific  immune lysis. B.  MOREIN,  D.  BARZ, U.  KOSZINOWSKI, AND V.  SCHIRRMACHER 
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FIG. 4.  ADCC  of P815 cells expressing SFV spike protein by virus infection or by attachment of 
the purified spike proteins as 29S complexes or virosomes. (O) Nontreated P815 cells; (m) SFV- 
infected P815 cells; (A) P815 cells with SFV-298 complexes  bound to the cell surface; (0) P815 cells 
with SFV-virosomes  bound to the cell surface. 
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Discussion 
Integration of a  virus membrane protein  into the lipid  bilayer of target cells has 
been shown to be essential for immune cytolysis. This came out from experiments in 
which the spike proteins of SFV were incorporated into target cell membranes from 
outside via fusion of virosomes. This kind of experiment demonstrating the successful 
transfer of a purified membrane protein from one particle (the virus) to another (the 
tumor target cell)  may be of general applicability and will therefore be discussed  in 
more detail. 
The spike proteins of SFV were first isolated  in detergent.  Because the detergent 
would interfere with the stability of the target cell membranes, it was either replaced 
by artificial  lipids  whereby  the  SFV  proteins  were reconstituted  into  lipid  vesicles 
(virosomes) or it was removed completely, whereby the spike proteins formed stable 
octamerous rosettes (29S complexes). Both the virosomes and the 29S complexes had 
the ability to attach to the murine tumor target cells. Such cells with attached SFV 
antigens could not be 1ysed by anti-SFV antibody and complement (CDL) or by anti- 
SFV  antibody  and  K  cells  (ADCC).  When,  however,  fusion  between  the  SFV- 
virosomes and  the  target  cell  membranes  was  made  possible  by  the  addition  of 
noninfectious SV as a fusing reagent, SFV-specific lysis was observed in both the CDL 
and the ADCC assay. Cells with attached  SFV-29S complexes remained resistant  to 
SFV-specific lysis even in the presence of the above SV preparation. 
These studies can be considered as an extension of previous liposome-cell interaction 
experiments  which  enabled  the  introduction  of the  haptenic  determinant  dinitro- 
phenyl into target cell membranes (21,  22, 23). The new aspects from our system are: 
(a)  use  of a  natural  membrane  protein  (SFV)  rather  than  a  lipophilic  artificial 
substance;  (b) comparison of different physical forms of the same membrane protein; 
and  (c)  separation  of the  fusion  process  itself by  using  an  independent  and  well- 
characterized antigenic  system as mediator for fusion. Thus  it could be shown  that 1392  SPECIFIC  CYTOLYSIS  AFTER  VIROSOME-TARGET  CELL  FUSION 
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with Staph-SV (50 #g/106 cells). 
cells incubated with SFV-virosomes could be lysed by anti-SFV antibodies only when 
SV  preparations  were  added  which  could  bind  to  and  fuse  with  the  target  cell 
membrane.  SV preparations which could still bind but  not  fuse because the F  had 
been inactivated by pretreatment with  trypsin did not  facilitate SFV-specific lysis, 
even when offered in a  500-fold excess. Separate controls with anti-SV antibodies or 
anti-SV CTL demonstrated that only those preparations which allowed SV-specific 
lysis and thus contained fusion activity also facilitated SFV-specific lysis. 
The stringent dependency of SFV-specific lysis on fusion between SFV-virosomes 
and the target cells excludes several alternative mechanisms of antigen transfer which 
could hitherto not be excluded in published studies on liposome cell interactions:  (a) 
simple diffusion, which can account for transfer of lipid molecules from bilayer vesicles 
upon contact  with cell membranes  (24,  25),  (b)  phagocytosis, driven by  metabolic 
energy, and  (c)  engulfment,  driven  by  surface-tension effects. The  data  are  more 
adequately  explained  by  vesicle-cell  membrane  fusion.  Although  the  sequence  of 
events at  the  molecular level is  not  known, it  could be anticipated  to proceed via 
vesicle-cell attachment, lipid bilayer perturbation brought about by the F of SV, and 
integration of the SFV spike protein together with adjacent artificial lipid into the 
target cell membrane (26).  Fusion activities have been reported for liposomes in the 
absence of a  specific fusing reagent.  Such  liposomes  had  to  have  a  low  transition 
temperature (high fluidity) and a  positive charge.  However, neutral liposomes with 
high fluidity such as phosphatidylcholine from egg yolk as were used in the present 
study were reported not to fuse spontaneously with cells (27). B. MOREIN, D.  BARZ, U. KOSZINOWSKI, AND V.  SCHIRRMACHER  1395 
Recent  studies  with  inactivated  SFV  rather  than  virosomes  indicate  that  very 
similar  results  can  be  obtained  (D.  Barz.  Unpublished  observations.):  target  ceils 
coincubated  with  SFV  in  the  absence  of a  fusing  reagent  were  resistant  to  SFV- 
specific lysis, whereas in the presence of a fusing reagent, they became susceptible. It 
thus seems that even the virus itself does not fuse spontaneously with the target cell 
membrane. It was recently demonstrated that SFV can enter target cells via endocy- 
tosis of membrane-bound viruses in coated vesicles and that these were the first steps 
on a pathway leading to productive cell infection (28). Together with our observations 
these studies indicate that SFV can enter target cells without fusing with the plasma 
membrane and thus without introducing susceptibility to immune cytolysis. With the 
help of a  fusing reagent, however, it seems to be possible to induce fusion of SFV or 
virosomes  with  target  cell  membranes  and  to  integrate  the  viral  spike  proteins. 
Electron-micrograph studies are underway to visualize this process of induced fusion. 
The above interpretation of vesicle-membrane fusion could also explain why the 
cells coated with the SFV-29S complexes, even in the presence of a  fusing reagent, 
could not be lysed by anti-SFV antibodies. These protein micelles, as a result of a lack 
of lipid  cannot  fuse with  membranes.  They are  held together by the  hydrophobic 
portions of the individual membrane proteins which interact with each other in the 
center of the complex. Studies by Helenius and Bonsdorff (4) and Helenius et al.  (5) 
have shown that the 29S complexes are very stable, difficult to break, and not suitable 
for reconstituiton into liposomes (A. Helenius. Personal communication.). Neverthe- 
less, it could be argued that the resistance to immune lysis of the cells carrying SFV 
antigens merely bound to the surface is a peculiarity of the SFV system and perhaps 
a  result of the fact that  this virus binds  to histocompatibility antigens.  This seems 
unlikely because resistance to lysis was also observed with SFV-29S complexes bound 
to cells at low pH (6.0-6.5). At low pH, many more 29S complexes can be bound per 
cell than at neutral pH which was explained by additional non-specific (i.e., not H-2 
mediated) binding (19). Because many of the experiments presented were performed 
under low pH conditions, the resistance to immune cytolysis of these cells seems to be 
more of general significance. Furthermore, similar results were obtained in other virus 
systems, such as SV used as a  control in these studies and vesicular stomatitis virus 
(29).  Lysis obtained by antisera against  other antigens than the viral proteins, e.g., 
non-H-2  antigens,  excluded  the  possibility  of intrinsic  changes  in  the  target  cell 
membranes or in the membrane repair system (30). 
A separate finding was made when using anti-H-2 sera for control. Here a partial 
reduction was observed in the specific lysis when comparing 29S complex-coated with 
noncoated target cells. This blocking effect was (a) selective for anti-H-2 sera (directed 
against the private specificities of the K- and D-end molecules) and (b) more prominent 
with P815 than with Eb tumor target cells. The selective blocking observed with anti- 
H-2 sera is explained by our previous demonstration that SFV binds to H-2K and D 
molecules (6). The differences between Eb and P815 cells could be explained by the 
different numbers of SFV  receptors determined  (1.9  ×  104/Eb cell and 0.2  ×  104/ 
P815 cell) (19). The chance of anti-H-2 antibodies to find free H-2 determinants and 
to efficiently activate complement may thus be greater with Eb than with P815 cells. 
The following conclusions can be reached from these studies: (a) integration of viral 
antigens  into the  lipid bilayer of target cells appears  as a  prerequisite for immune 
cytolysis; (b) immune eytolysis by antibody and complement (CDL), antibody and K 
cells  (ADCC),  and  by specific CTL share  this  prerequisite  which  may  indicate  a 1396  SPECIFIC  CYTOLYSIS AFTER  VIROSOME-TARGET CELL  FUSION 
common mechanism of at least part of the lytic process;  (c) cytolysis assays may serve 
as sensitive tests  for membrane  fusion and  for integration  of a  protein  into the lipid 
bilayer;  these  tests  have already  been  used  for this  purpose  (22,  23)  but  no formal 
proof for the  validity of this  assumption  has  existed  so  far;  and  (d)  the  transfer  of 
membrane  antigens  via  vesicles  and  a  fusing reagent  into  the  membranes  of other 
cells  may  find  a  useful  application  in  virus  or  tumor  systems  to  define  the  target 
molecules involved in immune cytolysis. 
Summary 
Structural requirements  for membrane antigens on target cells to mediate immune 
cytolysis  were  studied  in  a  model  system  with  purified  membrane  proteins  from 
Semliki  Forest  virus  (SFV).  These  SFV spike  proteins  were  isolated  in  the  form of 
detergent- and lipid-free protein micelles (29S complexes) or, after reconstitution into 
lipid  vesicles,  in  the  form of virosomes.  Both the  29S complexes and  the  virosomes 
were  found  to  bind  well  to  murine  tumor  cells  (P815  or  Eb).  When  these  cells, 
however,  were  used  as  target  cells  in  complement-dependent  lysis  or  in  antibody- 
dependent  cell-mediated  cytotoxicity assays in the presence of anti-SFV serum, they 
were not lysed, although they effectively bound the antibody and consumed comple- 
ment.  The same  tumor cells  infected  with  SFV  served  as  positive  controls  in  both 
assays. 
Different results were obtained when inactivated Sendai virus was added as a fusion 
reagent  to  the  cells  coated  with  either  virosomes  or  29S  complexes.  Under  these 
conditions the virosome-coated cells became susceptible to SFV-specific lysis, whereas 
the  29S complex-coated cells remained  resistant.  Evidence that  the susceptibility  to 
lysis ofvirosome-coated cells was dependent on active fusion and, therefore, integration 
of the viral antigens into the lipid bilayer of the target cells was derived from control 
experiments with enzyme-treated Sendai virus preparations. 
The 29S complexes and the virosomes partially and selectively blocked the target 
cell  lysis  by  anti-H-2  sera  but  not  by  anti-non-H-2  sera  confirming  our  previous 
finding that major histocompatibility antigens serve as receptors for SFV. The general 
significance of these findings for mechanisms of immune cytolysis is dicussed. 
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